M. Arning

8.4k total citations · 3 hit papers
53 papers, 6.1k citations indexed

About

M. Arning is a scholar working on Oncology, Epidemiology and Hematology. According to data from OpenAlex, M. Arning has authored 53 papers receiving a total of 6.1k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Oncology, 16 papers in Epidemiology and 16 papers in Hematology. Recurrent topics in M. Arning's work include Neutropenia and Cancer Infections (10 papers), Platelet Disorders and Treatments (8 papers) and Antifungal resistance and susceptibility (8 papers). M. Arning is often cited by papers focused on Neutropenia and Cancer Infections (10 papers), Platelet Disorders and Treatments (8 papers) and Antifungal resistance and susceptibility (8 papers). M. Arning collaborates with scholars based in Germany, United States and United Kingdom. M. Arning's co-authors include Annamaria H. Zimmermann, James B. Bussel, T. Oliver, J.T. Roberts, Luigi Dogliotti, Hans von der Maase, Gregory Cheng, Lisa Sengeløv, Malcolm J. Moore and Sergio Ricci and has published in prestigious journals such as New England Journal of Medicine, The Lancet and JAMA.

In The Last Decade

M. Arning

51 papers receiving 6.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Long-Term Survival Results of a Randomized Trial Comparing Gemcitabine Plus Cisplatin, With Methotrexate, Vinblastine, Doxorubicin, Plus Cisplatin in Patients With Bladder Cancer

2005 1.4k citations Annamaria H. Zimmermann, M. Arning et al. profile →
Adjuvant Chemotherapy With Gemcitabine and Long-term Outcomes Among Patients With Resected Pancreatic Cancer

2013 1.3k citations Helmut Oettle, M. Arning et al. profile →
Eltrombopag for the Treatment of Chronic Idiopathic Thrombocytopenic Purpura

2007 565 citations James B. Bussel, Gregory Cheng et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
M. Arning Germany	26	2.7k	2.3k	1.8k	1.4k	954	53	6.1k
Gabriela Kornek Austria	38	3.7k 1.4×	1.6k 0.7×	600 0.3×	1.7k 1.2×	799 0.8×	161	6.3k
P. Kosmidis Greece	39	3.9k 1.5×	1.0k 0.4×	734 0.4×	2.3k 1.7×	636 0.7×	224	6.4k
Bruce J. Roth United States	38	2.1k 0.8×	2.7k 1.2×	462 0.3×	1.7k 1.2×	773 0.8×	124	5.8k
Alan Yagoda United States	34	2.3k 0.9×	3.4k 1.5×	496 0.3×	1.9k 1.4×	584 0.6×	104	6.1k
K Takenaka Japan	33	1.2k 0.5×	1.4k 0.6×	648 0.4×	549 0.4×	950 1.0×	135	3.9k
F Bachmann Switzerland	42	670 0.2×	1.0k 0.4×	2.0k 1.1×	863 0.6×	466 0.5×	116	5.6k
Aristotelis Bamias Greece	36	3.1k 1.1×	1.9k 0.8×	383 0.2×	2.2k 1.6×	356 0.4×	276	6.9k
A. B. Miller Canada	4	3.6k 1.4×	1.4k 0.6×	491 0.3×	2.4k 1.7×	706 0.7×	6	6.8k
Ingo Schmidt‐Wolf Germany	20	2.7k 1.0×	831 0.4×	380 0.2×	717 0.5×	1.1k 1.1×	73	3.6k
W M Crist United States	41	2.0k 0.8×	818 0.4×	1.9k 1.0×	1.9k 1.3×	184 0.2×	75	6.1k

Countries citing papers authored by M. Arning

Since Specialization

Citations

This map shows the geographic impact of M. Arning's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. Arning with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. Arning more than expected).

Fields of papers citing papers by M. Arning

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. Arning. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. Arning. The network helps show where M. Arning may publish in the future.

Co-authorship network of co-authors of M. Arning

This figure shows the co-authorship network connecting the top 25 collaborators of M. Arning. A scholar is included among the top collaborators of M. Arning based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M. Arning. M. Arning is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Cheng, Gang, JB Bussel, Claus Werenberg Marcher, et al.. (2009). A phase III, double-blind, placebo-controlled study (RAISE) of eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura (ITP). Journal of Thrombosis and Haemostasis. 2 indexed citations

Psaila, Bethan, J B Bussel, Sandra Y. Vasey, et al.. (2008). EFFICACY AND SAFETY OF REPEATED INTERMITTENT TREATMENT WITH ELTROMBOPAG IN PATIENTS WITH CHRONIC IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP). 93. 120–120. 2 indexed citations

Bussel, James B., Gregory Cheng, Mansoor N. Saleh, et al.. (2007). Eltrombopag for the Treatment of Chronic Idiopathic Thrombocytopenic Purpura. New England Journal of Medicine. 357(22). 2237–2247. 565 indexed citations breakdown →

Kutikova, Lucie, Lee Bowman, Stella Chang, et al.. (2006). Medical costs associated with non-Hodgkin's lymphoma in the United States during the first two years of treatment. Leukemia & lymphoma. 47(8). 1535–1544. 38 indexed citations

Oettle, Helmut, Donald Richards, Rajesh Ramanathan, et al.. (2005). A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer. Annals of Oncology. 16(10). 1639–1645. 245 indexed citations

Roychowdhury, Debasish, et al.. (2002). A Report on Serious Pulmonary Toxicity Associated with Gemcitabine-Based Therapy. Investigational New Drugs. 20(3). 311–315. 69 indexed citations

Fung, Man C., et al.. (1999). A review of hemolytic uremic syndrome in patients treated with gemcitabine therapy. Cancer. 85(9). 2023–2032. 54 indexed citations

Fung, Man C., et al.. (1999). A review of hemolytic uremic syndrome in patients treated with gemcitabine therapy. Cancer. 85(9). 2023–2032. 115 indexed citations

Oettle, Helmut, Uwe Pelzer, Thomas Diebold, et al.. (1999). Phase I trial of gemcitabine (Gemzar®), 24 h infusion 5-fluorouracil and folinic acid in patients with inoperable pancreatic cancer. Anti-Cancer Drugs. 10(8). 699–704. 24 indexed citations

10.

Possinger, K., M. Kaufmann, Robert Coleman, et al.. (1999). Phase II study of gemcitabine as first-line chemotherapy in patients with advanced or metastatic breast cancer. Anti-Cancer Drugs. 10(2). 155–162. 107 indexed citations

11.

Lüftner, Diana, et al.. (1998). Gemcitabine plus dose-escalated epirubicin in advanced breast cancer: results of a phase I study. Investigational New Drugs. 16(2). 141–146. 22 indexed citations

12.

Withold, Wolfgang, M. Arning, Martin Schwarz, Hans‐Heinrich Wolf, & Wolfgang Schneider. (1998). Monitoring of multiple myeloma patients by simultaneously measuring marker substances of bone resorption and formation. Clinica Chimica Acta. 269(1). 21–30. 13 indexed citations

13.

Südhoff, T, et al.. (1997). Increases of sICAM-1 during neutropenic pneumonia in leukemic patients. Leukemia. 11(3). 346–351. 10 indexed citations

14.

Arning, M., et al.. (1995). Infusion‐related toxicity of three different amphotericin B formulations and its relation to cytokine plasma levels. Mycoses. 38(11-12). 459–465. 86 indexed citations

15.

Arning, M., et al.. (1995). Neutrophilic dermal infiltrates in granulocytopenic patients with acute leukemia. Annals of Hematology. 71(5). 257–261. 6 indexed citations

16.

Arning, M., et al.. (1995). Neutrophilic dermal infiltrates in granulocytopenic patients with acute leukemia. Annals of Hematology. 71(5). 257–261. 1 indexed citations

17.

Arning, M., et al.. (1991). Influence of Infusion Time on the Acute Toxicity of Amphotericin B: Results of a Randomized Double-Blind Study. Recent results in cancer research. 121. 347–352. 13 indexed citations

18.

Heyll, A., C. Aul, Michael J. Thomas, et al.. (1991). Granulocyte colony-stimulating factor (G-CSF) treatment in a neutropenic leukemia patient with diffuse interstitial pulmonary infiltrates. Annals of Hematology. 63(6). 328–332. 12 indexed citations

19.

Wolf, Hans‐Heinrich, et al.. (1990). Preliminary Results of Treatment with Itraconazole in Patients with Systemic Fungal Infections. Hämatologie und Bluttransfusion. 33. 560–562. 1 indexed citations

20.

Arning, M., et al.. (1989). Prevention of amphotericin-B-induced nephrotoxicity by loading with sodium chloride: A report of 1291 days of treatment with amphotericin B without renal failure. Journal of Molecular Medicine. 67(20). 1020–1028. 29 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact